Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Aim To assess the neuroprotective effect of Cop-1 (Copaxone) in reducing functional and structural damage after acute primary angle closure (APAC) Outcome measures: The primary outcome measures will be the point-wise linear regression in the visual fields. The secondary outcome measure will be the evaluation of structural changes, namely, RNFL thickness and Optic disc changes as measured by stratus OCT and HRT respectively. Study population The study population (n=196; 1:1 randomisation) will be patients with APAC attending the Singapore National Eye Centre who fulfil the inclusion criteria and are willing to take part in the study. Study design: The study design is a randomized, placebo controlled, double blinded trial where patients with APAC will be randomized to receive either Cop-1 (Copaxone) or placebo in addition to the standard medical therapy. An interim analysis will be conducted after 40 patients complete the trial. Routine examination will be done at all visits.